Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)

Yamaguchi, K; Bang, YJ; Iwasa, S; Sugimoto, N; Ryu, MH; Sakai, D; Chung, HCC; Kawakami, H; Yabusaki, H; Lee, J; Saito, K; Kawaguchi, Y; Kamio, T; Kojima, A; Sugihara, M; Shitara, K

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (4):

科室
- - 订阅+
  - 更多科室
工具
服务